MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates

Group 1 - MeiraGTx Holdings PLC reported a quarterly loss of $0.48 per share, which was better than the Zacks Consensus Estimate of a loss of $0.52, and an improvement from a loss of $0.76 per share a year ago, resulting in an earnings surprise of +7.69% [1] - The company posted revenues of $3.69 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 59.78%, compared to revenues of $0.28 million in the same quarter last year [2] - MeiraGTx shares have increased approximately 37% since the beginning of the year, outperforming the S&P 500's gain of 10% [3] Group 2 - The earnings outlook for MeiraGTx is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.53 on revenues of $2.77 million, and -$0.71 on revenues of $59.52 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Clene Inc., another company in the same industry, is expected to report a quarterly loss of $0.49 per share, reflecting a year-over-year change of +53.8%, with revenues anticipated to be $0.1 million, up 11.1% from the previous year [9]